Page 141 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

Appendix B

Public Workshop Agenda

Keck Center
E Street Conference Room
500 Fifth Street, NW, Washington, DC 20001

DAY 1: OCTOBER 29, 2018
OPEN SESSION

1:00pm	Opening Remarks to Public Audience
	Alan I. Leshner, Ph.D., Committee Chair Chief Executive Officer Emeritus American Association for the Advancement of Science
1:10pm	Presentation by Sponsoring Agencies
	Jack B. Stein, M.S.W., Ph.D. Director, Office of Science Policy and Communications National Institute on Drug Abuse Deepa Avula, M.P.H. Director, Office of Financial Resources Substance Abuse and Mental Health Services Administration Rebecca Baker, Ph.D. Special Assistant to the Director National Institutes of Health
1:30pm	Sponsor Q&A with Committee
	Alan I. Leshner, Committee Chair

Page 142 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

Time to ask clarifying questions to understand scope and charge of the Statement of Task

2:30pm

Adjourn Open Session

DAY 2: OCTOBER 30, 2018
OPEN SESSION

8:30am	Welcome and Opening Remarks
	Alan I. Leshner, Committee Chair Chief Executive Officer Emeritus American Association for the Advancement of Science Victor J. Dzau, National Academy of Medicine (via video)

SESSION 1: FEDERAL INITIATIVES

105-minute session (brief 5- to 7-minute panelist presentations followed by moderated discussion and Q&A)

8:45am	Objectives:
	Discuss current federal efforts to improve treatment for opioid use disorder (OUD) and access to medication-assisted treatment and hear perspectives from the study sponsors, National Institute on Drug Abuse and Substance Abuse and Mental Health Services Administration.
	Moderator:
	Alan I. Leshner, Committee Chair Chief Executive Officer Emeritus American Association for the Advancement of Science
	Panelists:
	Nora Volkow, National Institute on Drug Abuse Deepa Avula, Substance Abuse and Mental Health Services Administration Molly Evans, U.S. Centers for Disease Control and Prevention Judith Steinberg, Health Resources and Services Administration Rigo Roca, U.S. Food and Drug Administration
10:30am	BREAK

Page 143 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

SESSION 2: CURRENT EVIDENCE AND PRACTICE ON MEDICATION FOR TREATING OPIOID USE DISORDER

120 minutes (25-minute opening presentation followed by moderated panel discussion)

10:45am	Objectives:
	Discuss current evidence on the effectiveness of specific medications used to treat OUD. Identify evidence gaps that might contribute to limited effectiveness of specific medications or limit the use of medications in treating OUD, i.e., dosing ranges, optimal duration of treatments, discontinuation, optimal duration of tapering medication, and real-world evidence on patient experiences and preferences. For each medication, examine the regulations, infrastructure, and care settings required for delivery of specific medications for OUD, and explore how this influences patient and provider preference when selecting treatment. Discuss the evidence for behavioral counseling as a component of treatment for OUD. Are the current requirements for counseling evidence-based? Identify barriers to the use of specific medications, including any long-term side effects of medications for treating OUD and the perception and stigma of treatment options by patients, providers, the general public, and law enforcement.
	Moderator:
	Kathleen Carroll, Yale School of Medicine
	Opening Presentation:
	Charles O’Brien, University of Pennsylvania
	Panelists:
	Gavin Bart, University of Minnesota Michelle Lofwall, University of Kentucky Adam Bisaga, Columbia University Medical Center John Brooklyn, University of Vermont Maia Szalavitz, American reporter and author
12:45pm	LUNCH

Page 144 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

SESSION 3: IMPLEMENTATION AND UPTAKE: OPPORTUNITIES AND BARRIERS

1:45pm

Panel 3a: Opportunities and Barriers—Education and Training to Expand Treatment

(Brief 5- to 7-minute panelist presentations followed by moderated discussion and Q&A)

	Objectives:
	Examine the currently required education and training for providers treating OUD, and identify best practices and hurdles to achieving the required workforce to treat OUD. Explore the makeup of an ideal OUD treatment workforce, and discuss how this workforce may change based on care settings, populations, regions, and availability of medication for the treatment of OUD. Consider educational requirements for clinicians (surgical services, primary care, emergency departments, pharmacists), counselors, social workers, and others. Discuss what patient and family education or resources should be provided. Identify best practices and education for policy makers, law enforcement, the public, and other stakeholders.
	Moderator:
	Chinazo Cunningham, Albert Einstein College of Medicine
	Panelists:
	Jeanette Tetrault, Yale University Stephen Patrick, Vanderbilt University Eugenia Oviedo-Joekes, University of British Columbia Jules Netherland, Drug Policy Alliance Kathleen Johnson, Advocates for Opioid Recovery
3:15pm	BREAK

Page 145 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

3:30pm

Panel 3b: Opportunities and Barriers—Health Care Delivery, Payment Approaches, and Economics Measures to Improve Treatment of OUD

90 minutes (15-minute opening presentation followed by moderated panel discussion)

	Objectives:
	Discuss how health care access and delivery affect patient access to medications to treat OUD; consider regulations around hospital capacity, administrative burdens, and the tight regulation of medical products. Explore the cost, reimbursement, and coverage of medications to treat OUD, and discuss measures to help facilitate quality improvement and access. Examine regulatory differences of for-profit versus nonprofit treatment providers.
	Moderator:
	Colleen Barry, Johns Hopkins Bloomberg School of Public Health
	Opening Presentation:
	Richard Frank, Harvard University
	Panelists:
	Allan Coukell, Pew Charitable Trust Katrina King, George Mason University Yngvild Olson, Medical Director, Institutes for Behavior Resources, Inc.
5:00pm	Day 1 Recap and Closing Remarks
5:00pm	Alan I. Leshner, Committee Chair, Chief Executive Officer Emeritus, American Association for the Advancement of Science
5:15pm	Adjourn

Page 146 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

DAY 3: OCTOBER 31, 2018
OPEN SESSION

8:30am	Welcome and Opening Remarks
8:30am	Alan I. Leshner, Committee Chair Chief Executive Officer Emeritus American Association for the Advancement of Science
8:45am	Panel 3c: Opportunities and Barriers—Social Determinants of Health and Treatment for OUD

(Brief 5- to 7-minute panelist presentations followed by moderated discussion and Q&A)

	Objectives:
	Explore the impact of comorbidities on treatment and how this may affect the uptake and overall effectiveness of medications to treat OUD. Consider how pregnancy, age, race, gender, genetic variables, mental health, chronic pain, and other factors may influence treatment. Identify further evidence needed to better deliver culturally appropriate care and serve diverse populations.
	Moderator:
	David Patterson Silver Wolf, Washington University
	Panelists:
	Helena B. Hansen, New York University Josiah Rich, Brown University Anand Kumar, University of Illinois at Chicago Mishka Terplan, Virginia Commonwealth University
10:15am	BREAK

Page 147 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

SESSION 4: KNOWLEDGE GAPS—FUTURE
RESEARCH AND NEXT STEPS

90 minute session (brief 5- to 7-minute panelist presentations followed by moderated discussion and Q&A)

10:30am	Objectives:
	Discuss required research on U.S. Food and Drug Administration (FDA)-approved and non-FDA-approved medications for the treatment of OUD; consider patient preferences, delivery mechanisms, patient population (e.g., demographics or severity of OUD), and how different treatment settings may affect the research required. Identify patient outcome measures and process measures to facilitate the development of best practices for treating OUD. Identify research needs and policy changes to advance treatment and recovery.
	Moderator:
	Yasmin Hurd, Icahn School of Medicine at Mount Sinai
	Panelists:
	Sharon Walsh, University of Kentucky Gail D’Onofrio, Yale University Jonathan H. Watanabe, University of California, San Diego Jessica Hulsey Nickel, Addiction Policy Forum

SESSION 5: PUBLIC COMMENT

30-minute session

12:00pm	Objective:
	Members of the public are invited to sign up to provide comments on the workshop topic (3 minutes each)
	Moderator:
	Alan I. Leshner, Committee Chair Chief Executive Officer Emeritus American Association for the Advancement of Science

Page 148 Cite

Suggested Citation:"Appendix B: Public Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. doi: 10.17226/25310.

×

12:30pm	Meeting Recap and Closing Remarks
12:30pm	Alan I. Leshner, Committee Chair Chief Executive Officer Emeritus American Association for the Advancement of Science
12:45pm	Adjourn